-100%

est. 2Y upside i

HealthcareSeries C

Rank

#4022

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Low

Equity in Kariusdx offers essentially no expected upside due to severe preference overhang: total funding of $409M exceeds the secondary market valuation of $320M, meaning common stock is out of the money even at the entry price.

Last updated: July 3, 2026

Bull (10%)-100%

Revenue grows to $16.5M by 2028, but exit multiple of 7x yields $115.8M, far below $409M preference. Common stock recovers 0. Bull probability reduced due to high incumbent threat and no IPO catalyst.

Base (35%)-100%

Revenue grows modestly to $16.5M, exit at 5x multiple gives $82.7M. Preference stack absorbs all value, common worthless. Base case reflects moderate growth and competitive pressures.

Bear (55%)-100%

Revenue stagnates or declines, exit multiple compresses to 3x, enterprise value ~$49.6M. Preference stack far exceeds exit, common zero. Bear case driven by high capital intensity and intense incumbent competition.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

12780%

Total funding of $409M exceeds the entry valuation of $320M, creating a 128% preference overhang. Common stock has no value unless the exit exceeds the liquidation preference.

Dilution Risk

high

Given the high burn rate and limited revenue, a capital raise within 24 months is likely, which would further dilute common equity and increase the preference stack.

Secondary Liquidity

limited

Secondary trades exist at a $320M implied valuation, but volume is likely thin. The primary route to liquidity remains an IPO or acquisition, which is uncertain.

Commercial — 9 roles

Clinical & Medical — 4 roles

General & Administrative — 1 role

General Inquiry — 1 role

Research & Development — 1 role

View all 16 open roles at Kariusdx →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Kariusdx's data — designed to show you've done your homework.

  • 1

    “What is the company's strategy to scale revenue beyond the current $10.6M given the high competition from incumbents like Roche and Thermo Fisher?”

  • 2

    “How does the Karius test's reimbursement landscape look, and what are the gross margin improvement plans?”

  • 3

    “Given the preference overhang, what is the realistic path to liquidity for common shareholders, and what is the expected timeline?”

Community

Valuation Sentiment

Our model estimates -100% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.